Ajay Gannerkote, President, Integrated DNA Technologies examines how AI is helping to advance the drug discovery landscape. In the past decade, few fields in biotechnology have evolved as dramatically as gene synthesis and genome engineering. The evolution of digital technologies, particularly the advent of artificial intelligence (AI), has resulted in… Read More
A collaborative project led by the Max-Planck Institute of Molecular Plant Physiology (MPI-MP), Germany, aims to develop synthetic chloroplast genomes. Enzymatic DNA synthesis company Camena Bioscience and whole genome writing specialists Constructive Bio are the latest companies to join the project. Until now, constructing synthetic… Read More
Dr Thomas Ybert, Co-founder and Chief Scientific Officer at DNA Script, describes how recent advancements in enzymatic DNA synthesis are unlocking previously inaccessible regions of the genome. Synthetic nucleic acids are foundational tools in biological research and therapeutic development, essential for applications ranging from gene synthesis to mRNA vaccine templates. Read More
Christian Schafmeister, Founder and President of Thirdlaw Molecular, explores the promise of Goldilocks-sized molecules, the chemistry and design principles behind them and the technologies enabling rapid development of high-affinity binders against previously undruggable targets. For decades, the pharmaceutical industry has thrived on a foundational paradigm: small molecules for intracellular targets… Read More
This is the latest episode of the free DDW narrated podcast, titled “An overview on the impact of synthetic biology”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Synthetic biology: Impacting drug discovery” and “Synthetic biology: Innovating in drug… Read More
This is the latest episode of the free DDW narrated podcast, titled “How is precision medicine making its mark in drug discovery?”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Accelerating biotherapy and personalised medicine with long DNA”… Read More
A new webinar is now open for registration entitled ‘Using ENFINIA cell-free synthesised DNA for rapid protein expression and screening in the myTXTL cell-free system‘. Cell-free transcription-translation (TXTL) systems can be used for rapid and flexible protein expression and screening workflows, powering protein engineering and discovery, synthetic biology, AI-driven… Read More
A new webinar is now open for registration entitled ‘Using ENFINIA cell-free synthesised DNA for rapid protein expression and screening in the myTXTL cell-free system‘. Cell-free transcription-translation (TXTL) systems can be used for rapid and flexible protein expression and screening workflows, powering protein engineering and discovery, synthetic biology, AI-driven… Read More
A new webinar is now open for registration entitled ‘Using ENFINIA cell-free synthesised DNA for rapid protein expression and screening in the myTXTL cell-free system‘. Cell-free transcription-translation (TXTL) systems can be used for rapid and flexible protein expression and screening workflows, powering protein engineering and discovery, synthetic biology, AI-driven… Read More
A new webinar is now open for registration entitled ‘Using ENFINIA cell-free synthesised DNA for rapid protein expression and screening in the myTXTL cell-free system‘. Cell-free transcription-translation (TXTL) systems can be used for rapid and flexible protein expression and screening workflows, powering protein engineering and discovery, synthetic biology, AI-driven… Read More
Cell-free transcription-translation (TXTL) systems can be used for rapid and flexible protein expression and screening workflows, powering protein engineering and discovery, synthetic biology, AI-driven approaches, biomanufacturing, and more. However, reliance on plasmid DNA templates for expression requires time-consuming cloning steps, limiting speed and efficiency. In this webinar, supported by Elegen,… Read More
Researchers at Tokyo University of Science have successfully developed a new method to synthesise eutyscoparol A and violaceoid C, two naturally occurring compounds with promising antimalarial and antibacterial properties. The new approach involves the synthesis of these compounds using readily available dinitriles. This method requires fewer… Read More
Abiologics, a Flagship Pioneering company, has launched to develop a new class of supranatural and programmable medicines called Synteins. Synteins are computationally-generated and synthesised with novel building blocks, potentially providing treatments across a wide range of diseases. Flagship has initially committed $50 million to… Read More
Dr Pandora Pound, Fellow Oxford Centre for Animal Ethics explores the hinderances of animal testing in pharma and why new technologies such AI, genomics and synthetic biology can further… Read More
A new technique to clone and reassemble DNA could simplify and lower the cost of making synthetic chromosomes, according to its creators at University of Southern California (USC) Dornsife. Known as ‘CReATiNG’ (Cloning Reprogramming and Assembling Tiled Natural Genomic DNA), the method offers a simpler and… Read More
This is the latest episode of the free DDW narrated podcast, “Outside the box thinking for drug discovery success”, which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Stanford researchers construct the most complete synthetic microbiome, … Read More
